Response to "ACE-2 Downregulation and Incidence of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Infection".
Response to "ACE-2 Downregulation and Incidence of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Infection".
复制标题
对“ACE-2 下调和严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2) 感染的发生率”的回应。
DOI：
10.1093/ajh/hpaa212
复制
发表时间：
2021
影响因子：
3.2
通讯作者：
Psaty,BruceM
中科院分区：
文献类型：
--
作者：
Dublin,Sascha;Walker,RodL;Floyd,JamesS;Shortreed,SusanM;Fuller,Sharon;Albertson-Junkans,Ladia;Harrington,LauraB;Greenwood-Hickman,MikaelAnne;Green,BeverlyB;Psaty,BruceM
We appreciate the questions raised by Drs Weir, Glen, and McDowell in their letter to the Editor referencing our recent paper about severe acute respiratory syndrome–coronavirus-2 (SARS–CoV-2) infection in relation to the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). 1 They propose that inhibiting ACE-2, the receptor by which SARS–CoV-2 enters cells, might be beneficial in preventing infection or severe outcomes and ask whether we could examine the association between the use of aliskiren, a direct renin antagonist thought to downregulate ACE-2, and risk of SARS–CoV-2 infection or severe disease. We looked at our data and found that in the population we studied, aliskiren use was so rare that we would not have adequate power to examine this question. In the past year, patients in our healthcare system were dispensed fewer than 30 prescription fills for aliskiren. For comparison, there were about 150,000 medication dispensings for lisinopril, the most commonly used ACEI. The idea that downregulation of ACE-2 could protect against SARS–CoV-2 infection or severe disease is intriguing and warrants further exploration. We would be interested to know if there are other, more commonly used medications that downregulate ACE-2 that could be the subject of future research.
